HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • HealthEconomics.Com On-demand Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts

Geisinger Program Slows Spending Growth on Biologics

A comparative effectiveness program launched by Geisinger Health has reportedly slowed the rapid increase in biologic spending, according to an HFMA report. According to the report, Geisinger Health Plan's spending on biologics accounted for about 35.9 percent of its total drug spending in 2018, […]

more info 04/19/2019View Related Articles
Bookmark and Share

ICER Set to Review Canakinumab for Atherosclerosis

The Institute for Clinical and Economic Review (ICER) on Monday announced its plans to analyze the comparative clinical effectiveness and value of Novartis' canakinumab to reduce cardiovascular risk in patients diagnosed with atherosclerosis. ICER in a press release said the report will be reviewed […]

more info 06/19/2018View Related Articles
Bookmark and Share

IBD Therapy Trial Receives $2.4 Million Grant

A comparative study of new biologic and small-molecule treatments for inflammatory bowel disease is slated to receive $2.4 million in grant funding from the Patient-Centered Outcomes Research Institute and the Crohn's and Colitis Foundation (CCF). According to a Healio report, the study will […]

more info 05/17/2018View Related Articles
Bookmark and Share

ICER Releases Report on Plaque Psoriasis Treatments

The Institute for Clinical and Economic Review (ICER) on Friday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for moderate-to-severe plaque psoriasis. The review will be open to public comment until May 25. Findings contained in this […]

more info 04/28/2018View Related Articles
Bookmark and Share

ICER Set to Review Biologic Treatments for Asthma

The Institute for Clinical and Economic Review (ICER) on Tuesday announced plans to develop a review assessing the comparative clinical effectiveness and value of biologic therapies for moderate-to-severe asthma. The report is set to be reviewed during a November public meeting of the Midwest […]

more info 04/25/2018View Related Articles
Bookmark and Share

Articles in Journal Highlight Efforts to Better CER

Three articles in the Journal of Comparative Effectiveness Research focus on the work and recommendations of a CER-centric conference convened last year by the PhRMA Foundation and the Academy of Managed Care Pharmacy. The articles push for steps that aim to ensure future decisions regarding […]

more info 02/26/2018View Related Articles
Bookmark and Share

ICER Reports to Assess Amyloidosis, Prostate Cancer Treatments

The Institute for Clinical and Economic Review (ICER) says upcoming reports will focus on the comparative clinical effectiveness and value of high-risk prostate cancer and hereditary amyloidosis treatments. According to a press release, the reports will be reviewed during the September meeting of […]

more info 02/17/2018View Related Articles
Bookmark and Share

What Role do Payers Play in the Opioid Crisis?

Listen to Judy Zerzan from the Colorado Department of Health Care Policy & Financing talk on the role of payers in the opioid crisis in this short clip.  View here. (Source: PCORI, 1/23/18) […]

more info 02/01/2018View Related Articles
Bookmark and Share

ICER Releases Report on Emicizumab for Hemophilia A

The Institute for Clinical and Economic Review recently released a Draft Evidence Report assessing the comparative clinical effectiveness and value of emicizumab. The Draft Evidence Report and Draft Voting Questions are now open to public comment until February 23rd at 5 PM ET. Find out more here.  […]

more info 01/26/2018View Related Articles
Bookmark and Share

German Drug Assessment Watchdog Pushes Direct Comparison of Cancer Immunotherapies

IQWiG, and independent drug assessment body in Germany, is pushing for direct comparison data in a new class of cancer immunotherapies. The move comes as the watchdog speaks out against what it says is a lack of data in the class of immunotherapies, suggesting physicians could be either overwhelmed […]

more info 01/17/2018View Related Articles
Bookmark and Share

ICER Report Recommends Voretigene Neparvovec Price Discount

The Institute for Clinical and Economic Review (ICER) on Friday released its revised Evidence Report assessing the comparative clinical effectiveness and value of voretigene neparvovec (Luxturna, Spark Therapeutics) for treatment of vision loss associated with biallelic RPE65-mediated retinal […]

more info 01/12/2018View Related Articles
Bookmark and Share

BSBSA Chief Medical Officer: CER ‘Very Critical When You Have Options’

Blue Cross Blue Shield Association Chief Medical Office Trent Haywood discussed comparative effectiveness research and how it could facilitate personalized decisions on health care. "Comparative effectiveness research, to me, is very critical when you have options, and when you're considering the […]

more info 01/10/2018View Related Articles
Bookmark and Share

ICER to Assess Elagolix for Management of Endometriosis

The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and value of elagolix (AbbVie) for management of endometriosis with associated pain. The FDA’s decision on whether to approve elagolix is expected during the second quarter of 2018. An Open […]

more info 12/15/2017View Related Articles
Bookmark and Share

ICER to Assess Erenumab for Migraines, Guselkumab and Tildrakizumab

The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and value of erenumab (Amgen/Novartis) for prevention of migraine headaches. The FDA’s decision on whether to approve erenumab is expected in May of 2018. In addition, ICER will conduct an […]

more info 11/10/2017View Related Articles
Bookmark and Share

ICER Releases Report on Tardive Dyskinesia Treatments

ICER logo for Berger report

The Institute for Clinical and Economic Review(ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder often associated with long-term use of antipsychotic medications. The report, along with […]

more info 10/07/2017View Related Articles
Bookmark and Share

ICER Publishes Report on Mind-Body Therapies

ICER logo for Berger report

The Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness of several cognitive and mind-body therapies for treatment of chronic low back and neck pain, including acupuncture, cognitive behavioral therapy (CBT), […]

more info 10/07/2017View Related Articles
Bookmark and Share

Biopharma Companies Pledge $500,000 to PAI’s hēRo3

PAI announced three biopharma companies have pooled $500,000 for the final development phase of its hēRo3, a new open-source platform for running cost-effectiveness models. The platform is slated to undergo extensive testing in October by PAI's development partners and HTA agencies. After testing, […]

more info 09/29/2017View Related Articles
Bookmark and Share

Health Affairs Blog: RWE a Welcome Addition to Randomized Controlled Trials

Health care photo

A Health Affairs Blog post says real-world evidence (RWE) complements randomized controlled trials, which sometimes have limitations in comparative effectiveness research. As the health care industry begins its slow shift toward a more value-based payment system, accurate and reliable data is […]

more info 09/28/2017View Related Articles
Bookmark and Share

Eyeforpharma Spotlights Data, Pragmatic Trials in Interview

The undeniable power of data is becoming more apparent by the day, and is poised to revamp the current health care landscape through real-world data. Eyeforpharma sat down with Janssen Real-World Evidence Team Leader Jack Sheehan and Riccardo Perfetti, Sanofi senior medical officer and vice […]

more info 09/27/2017View Related Articles
Bookmark and Share

Outcomes-Based Pricing for PCSK9 Inhibitors

Via the American Journal of Managed Care: "In 2015, the FDA approved the PCSK9 inhibitors evolocumab and alirocumab for lowering low-density lipoprotein cholesterol (LDL-C). The approval of these agents was based on clinical trials that found PCSK9 inhibitors reduced LDL-C levels by around […]

more info 09/27/2017View Related Articles
Bookmark and Share

FDA Urges Stronger Clinical Research

U.S. Food and Drug Administration (FDA) officials and health care industry leaders say it's necessary to reassess the standards of evidence and dependability of information during regulatory discussions, Applied Clinical Trials reports. FDA Commissioner Scott Gottlieb at an Impact of Real World […]

more info 09/27/2017View Related Articles
Bookmark and Share

ICER Posts Draft Scoping Document for Emicizumab Review

ICER Logo

Via the Institute for Clinical and Economic Review: The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document outlining its planned review of the comparative clinical effectiveness and value of emicizumab for prevention of bleeding in patients with hemophilia A who […]

more info 09/14/2017View Related Articles
Bookmark and Share

ICER: Inadequate Evidence to Compare PARP Inhibitors Across Ovarian Cancer Indications

The Institute for Clinical and Economic Review on Wednesday published an evidence report on the comparative clinical effectiveness and value of three inhibitors used in ovarian cancer treatments. "PARP inhibitors have the potential to improve upon existing treatment paradigms for women who […]

more info 09/01/2017View Related Articles
Bookmark and Share

VIDEO: NPC Research VP Discusses Decision-Making by Payers

The National Pharmaceutical Council's Vice President of Comparative Effectiveness Research Jennifer Graff says payers use a wide swath of information to make coverage and reimbursement decisions. Graff said in an interview with the American Journal of Managed Care that the best evidence could […]

more info 08/03/2017View Related Articles
Bookmark and Share

VIDEO: PCORI Executive Director talks CER

In a video posted Thursday by the Patient-Centered Outcomes Research Institute, Joe Selby, the institute's executive director, discussed some challenges facing efficient comparative effectiveness research.  "There are a lot of methodological questions about how one does comparative effectiveness […]

more info 07/28/2017View Related Articles
Bookmark and Share

Correlating Surrogate Endpoints with RWE in Oncology

Via the American Journal of Managed Care: "A new study has analyzed data from randomized controlled trials (RCTs) in oncology that used surrogate endpoints and measured their relation with treatment effectiveness and patient survival in the real world. A significant concern with using surrogate […]

more info 07/28/2017View Related Articles
Bookmark and Share

Goodman: Value Frameworks Always Evolving

Clifford Goodman, senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group, said in an interview value frameworks are continually evolving and adapting in the health care marketplace. "Value frameworks also recognize that value is the in the eye of […]

more info 07/26/2017View Related Articles
Bookmark and Share

ICER: Osteoporosis Anabolic Agents Priced Too High

ICER logo for Berger report

In a Final Evidence Report on the comparative clinical effectiveness and value of teriparatide and abaloparatide, the Institute of Clinical and Economic Review (ICER) found the price of both agents was "too high." Teriparatide and abaloparatide are anabolic agents used in osteoporosis […]

more info 07/19/2017View Related Articles
Bookmark and Share

Same Condition, Different Costs: NPC to Address Contentious Question

The National Pharmaceutical Council (NPC) will bring to focus a contentious issue in the health care industry: Why do some patients with the same condition sometimes have different out-of-pocket costs than others for their medicines? In a free, online webinar titled "Same Condition, Different […]

more info 07/12/2017View Related Articles
Bookmark and Share

ICER Announces Draft Scoping Document on Retinal Disease Therapy

ICER logo for Berger report

The Institute for Clinical and Economic Review (ICER) posted a Draft Scoping Document which will be involved in a report on voretigene neparvovec. According to a press release from ICER, voretigene neparvovec is a therapy used to help people suffering from "vision loss associated with biallelic […]

more info 07/12/2017View Related Articles
Bookmark and Share

  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

    No feed items found.

 
Syndicated Reports

Economic & Related Consulting Service Revenues World Report & Database

Healthcare Analytical Testing Services Market worth $9.8 billion by 2026 – Key Players are Eurofins Scientific, SGS S.A., Charles River Laboratories

Risk-Based Monitoring Software Market Worth $511 Million By 2025 – Growing Number Of Clinical Trials To Propel Market Growth

Real-World Evidence Solutions Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)

 
White Papers

The Augmented Rep: A practical field force guide for the Omnichannel era

Rare Disease’s Star Turn

The Next Generation of Information Management

Risk Mitigation for Pharma Manufacturer Programs

HealthEconomics.Com

HealthEconomics.Com

  • Become a Better Writer!
  • HealthEconomics.Com Recognized as Top Influencer at ISPOR International Meeting in Washington DC
  • Will ICER Framework Destroy Progress Against Multiple Myeloma?
  • Celgene Unleashes the Power of Data into Clinical Trial Design
  • How Well is Harvoni Working in the Real World?
  • New CVS and Express Scripts Value Based Plans for Oncology
  • Oversized Cancer Drug Vials Waste $3B Each Year
  • Can More Data Make Providers’ Jobs Easier?
  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Take This Survey for a Chance to Win $200!
  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • ICER Releases Two Draft Reports on Obeticholic Acid
  • What do Patient Advocates Think of New ICER Report?
  • Could a New ICER Report Put Patients at Risk?
  • Contact Us

About

  • International Myeloma Foundation Responds to ICER Report
  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • HealthEconomics.Com On-demand Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts